key: cord-0829732-i9odfs51
authors: DeMets, David L.; Fleming, Thomas R.
title: Achieving Effective Informed Oversight by DMCs in COVID Clinical Trials
date: 2020-07-10
journal: J Clin Epidemiol
DOI: 10.1016/j.jclinepi.2020.07.001
sha: 743c09777c0686fef7ac0dfed8d7a21309bed22e
doc_id: 829732
cord_uid: i9odfs51

Abstract Best practices of Data Monitoring Committees (DMCs) in randomized clinical trials are well established. Independent oversight provided by DMCs is particularly important in trials conducted in public health emergencies, such as in HIV/AIDS or coronavirus epidemics. Special considerations are needed to enable DMCs to effectively address novel circumstances they face in such settings. In the COVID-19 pandemic, these include the remarkable speed in which data regarding benefits and risks of interventions are accumulated. DMCs must hold frequent virtual meetings, using state-of-the-art communication software that protects against risk for security breaches. Data capture and DMC reports should be focused on the most informative measures about benefits and risks. Since numerous clinical trials are being concurrently conducted in the COVID-19 setting, often addressing closely related scientific questions, structures for DMC oversight should be efficient and adequately informative. When these concurrently conducted trials are evaluating related regimens in related clinical settings, often individually underpowered for safety and having separate DMCs, processes should be implemented enabling these DMCs to share with each other emerging confidential evidence to better assess risks and benefits. Ideally a single DMC would monitor a portfolio of clinical trials or a trial with multiple arms, such as a platform trial.

include the remarkable speed in which data regarding benefits and risks of interventions 

Based on the Helsinki agreements, trials should not continue longer than necessary to 58 answer the questions they are designed to address (1). Trials may be terminated due 59 to overwhelming benefit, convincing evidence of harm or lack of benefit, or logistical 60 problems that cannot be corrected. To accomplish their mission of safeguarding 61 participant interests while enhancing trial integrity, the DMC meets periodically to review 62 accumulating data on primary and secondary outcomes, safety, and quality of trial and secondary outcomes and on safety domains needed to be kept confidential until the 92 results reliably answered the questions each trial was designed to address (8, 9) .

Maintaining confidentiality of accumulating interim results, a challenge given the number 94 of interested stakeholders, was essential to ensuring the integrity of ongoing trials. To 95 meet the legitimate needs of these stakeholders, this DMC needed to make changes in 96 the structure of their meetings.

At the beginning of the meeting for each trial, a closed session was held to enable DMC 98 members to discuss privately key elements of the emerging data and share concerns 99 that had been identified from their review of each study's closed DMC report containing holding DMC meetings appears to be working well, given the risk for security breaches 136 created by external hackers, effective procedures must be in place in COVID-19 trials to 137 protect the confidentiality of interim data and the DMC review process.

Given the corresponding acceleration in the rate of data generation, the process for 

Data Monitoring Committees in Clinical 249 Trials: A Practical Perspective

Data Monitoring in Clinical Trials: A Case Studies 252 Approach

Clinical Trials: Recommendations for Data Monitoring Committees from the 262

The Data and Safety Monitoring Board and acquired immune 266 deficiency syndrome (AIDS) clinical trials

Data monitoring committees: expect the unexpected

Maintaining confidentiality of interim 270 data to enhance trial integrity and credibility

Data monitoring issues: current issues

Drug Evaluation during the Covid-19 Pandemic

Finding Effective Treatments for COVID-19: Scientific 276 Integrity and Public Confidence in a Time of Crises

Fundamentals of

Zidovudine alone or in combination

Over the past five decades, the process of monitoring ongoing randomized clinical trials (RCTs) by means of an independent data monitoring committee (DMC) for safety and benefit has evolved(1-2). In March of 2020, the World Health Organization (WHO) declared COVID-19 disease to be a pandemic and numerous trials began soon thereafter to provide timely evaluations of vaccines and therapeutics. This article discusses challenges that the COVID-19 trials bring to the DMC process, influenced by the speed at which the epidemic is spreading, patients are being recruited and outcome data for benefit and risk are accumulating. The independent oversight provided by DMCs is perhaps even more important in trials for extreme emergencies such as the HIV/AIDS or coronavirus epidemics.Dr. Fleming reported receiving personal fees from industry sponsors for service on Data Monitoring Committees, research support from the National Institutes of Health, and extensive interactions in coronavirus disease 2019 (COVID-19) research with the World Health Organization Research and Development Working Group